title: Somatostatin receptor type 5 modulates somatostatin receptor type 2 regulation of adrenocorticotropin secretion.
abstract: Somatostatin inhibits adrenocorticotropin (ACTH) secretion from pituitary tumor cells. To assess the contribution of somatostatin receptor subtype 5 (SST5) to somatostatin receptor subtype 2 (SST2) action in these cells, we assessed multipathway responses to novel highly monoreceptor-selective peptide agonists and multireceptor agonists, including octreotide and somatostatin-28. Octreotide and somatostatin-28 cell membrane binding affinities correlated with their respective SST2-selective peptide ligand. Although octreotide had similar inhibiting potency (picomolar) for cAMP accumulation and ACTH secretion as an SST2-selective agonist, somatostatin-28 exhibited a higher potency (femtomolar). Baseline spontaneous calcium oscillations assessed by fluorescent confocal microscopy revealed two distinct effects: SST2 activation reduced oscillations at femtomolar concentrations reflected by high inhibiting potency of averaged normalized oscillation amplitude, whereas SST5 activation induces brief oscillation pauses and increased oscillation amplitude. Octreotide exhibits an integrated effect of both receptors; however, somatostatin-28 exhibited a complex response with two separate inhibitory potencies. SST2 internalization was visualized with SST2-selective agonist at lower concentrations than for octreotide or somatostatin-28, whereas SST5 did not internalize. Using monoreceptor-selective peptide agonists, the results indicate that, in AtT-20 cells, SST5 regulates the dominant SST2 action, attenuating SST2 effects on intracellular calcium oscillation and internalization. This may explain superior somatostatin-28 potency and provides a rationale for somatostatin ligand design to treat ACTH-secreting pituitary tumors.
authors.affiliation: Department of Medicine, Cedars Sinai Research Institute, David Geffen School of Medicine, UCLA, Los Angeles, California 90048, USA.
authors.forename: Anat
authors.initials: A
authors.lastname: Ben-Shlomo
authors.forename: Kolja A
authors.initials: KA
authors.lastname: Wawrowsky
authors.forename: Irina
authors.initials: I
authors.lastname: Proekt
authors.forename: Nathaniel M
authors.initials: NM
authors.lastname: Wolkenfeld
authors.forename: Song-Guang
authors.initials: SG
authors.lastname: Ren
authors.forename: John
authors.initials: J
authors.lastname: Taylor
authors.forename: Michael D
authors.initials: MD
authors.lastname: Culler
authors.forename: Shlomo
authors.initials: S
authors.lastname: Melmed
mesh_terms: D000236:Adenoma / Q000378:metabolism; D000324:Adrenocorticotropic Hormone / Q000378:metabolism*; D000818:Animals; D001483:Base Sequence; D015153:Blotting, Western; D045744:Cell Line, Tumor; D017931:DNA Primers; D047468:Immunoprecipitation; D051379:Mice; D018613:Microscopy, Confocal; D008856:Microscopy, Fluorescence; D010911:Pituitary Neoplasms / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000502:physiology*
chemical_list: D017931:DNA Primers; D017481:Receptors, Somatostatin; C094573:somatostatin receptor 5; D000324:Adrenocorticotropic Hormone; C093733:somatostatin receptor 2